65,437 trials
Hodgkin Lymphoma · Anaplastic Large-cell Lymphoma
Primary: Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, Predose — NA; NA; NA; NA ng/mL
Obesity
Primary: Change in iGFR (Glomerular Filtration Rate as Measured by Iohexol Clearance) From Baseline to End of Treatment — -14.92; 1.08 mL/min/1.73 m^2
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) on Day 85 — 0.154; 0.095 Liter — p=<0.001
Type 2 Diabetes
Primary: Frequency of Adverse Drug Reactions — 1; 7; 1; 1 participants
Carcinoid Syndrome
Primary: Percentage of Days With Subcutaneous Octreotide as Rescue Medication — 33.72; 48.49 Percentage of days — p=0.0165
Cervical Pain
Primary: Percent of Peak Activation (%PA) — 51.72; 61.20; 88.1; 80.80 Percentage of Peak Activation (%PA)
Metastatic Colorectal Cancer
Primary: PFS Hazard Ratio — 0.365 months — p=0.0130
Chronic Myelogenous Leukemia in Chronic Phase
Primary: Number of Participants With Confirmed Complete Molecular Response (CMR) — 34 Participants
Lymphoma
Primary: Assessment of Tumor Response — 30.3; 54.5 percentage of participants
Schizophrenia · Insomnia Related to Schizophrenia (307.42)
Primary: Pittsburgh Sleep Quality Index — 6.1 global score — p==0.002
Wound Infection
Primary: Number of Operating Room Visits — 2.5; 2.8 Operative Room Visits
HIV
Primary: Number of Participants Who Died and With Adverse Events (AEs) Leading to Discontinuation, Hyperbilirubinemia, Jaundice, First-degree Arterioventricular Block…
Non-Small Cell Lung Cancer
Primary: Overall Survival — 21.5; 24.1 Months — p=0.883
Presbyopia
Primary: Visual Performance - Comparison of Initial Refraction to Multifocal Lenses — 65.3; 48.3; 49.1 percentage of participants
Unresectable Melanoma · Metastatic Melanoma
Primary: Objective Response Rate (ORR) - BRAF Wild-type (WT) Participants — 60.3; 10.8 Percentage of participants